Together for Tomorrow: Explore New Treatment Options for Lung Cancer

V
Vijaya L. Kakani, MD

Primary Investigator

Together for Tomorrow: Explore New Treatment Options for Lung Cancer
Recruiting
18 years - 100 years
All
Phase 3
1 participants needed
1 Location

Brief description of study

We understand that living with non-small cell lung cancer (NSCLC), especially with the KRAS G12C mutation, can be incredibly challenging.   Many people with lung cancer go through hard treatments and tough side effects. 

That's why we're inviting adults (ages 18 and older) who have advanced or metastatic nonsquamous NSCLC to participate in our study.  The goal is to find out if a investigational combination of targeted therapy and immunotherapy can help you live longer without your cancer growing or spreading as compared to traditional chemotherapy treatment.

We're also hoping that this study helps us find ways to:

  • Slow down cancer growth
  • Use treatments that target cancer more directly
  • Learn if fewer or different side effects are possible
  • Improve quality of life

Participating in this study offers you a chance to explore new treatment options while helping researchers learn more about effective therapies for lung cancer. 

If you want to make a difference for yourself and others, consider joining us.

Detailed description of study

If you decide to join our study, here’s what will happen:

1. Screening: It will take about 4-6 weeks to check your eligibility. During this time, a study doctor will review your medical history and test results to see if this study is a good fit for you. All screening visits will take place at Arnett Cancer Center (420 N 26th St, Lafayette, IN, United States, 47904).

2. Random Assignment: This study will look at two treatment plans to see which one works better for you.  You will be randomly assigned (like the flip of a coin) to either Group A or Group B. This means you won’t know which treatment you’ll receive until it starts.

  • Group A: You will receive a combination of MK-1084 (a targeted therapy) and MK-3475A (a type of immunotherapy).
  • Group B: You will receive MK-3475A along with traditional chemotherapy (carboplatin or cisplatin with pemetrexed).

3. Treatment: Each treatment lasts about 2 years, during which time you’ll receive regular checkups and follow-ups over an additional 3 years (total study participation is up to 5 years).  All study visits will take place at Arnett Cancer Center (420 N 26th St, Lafayette, IN, United States, 47904).

4.  Monitoring: You'll receive careful monitoring of your health to see how you respond to the treatments and our team will support you throughout the process.

5. Compensation: You'll receive a visit stipend of $50.00 per completed study visit. Reasonable travel expenses for trial-related visits, including unscheduled visits, may also be covered.  Stipends for companions are also available. The research team will explain this further during your screening visit.

Things you should know:

  • You can stop the study at any time.
  • If the cancer grows, the study doctor will talk with you about next steps.
  • Some people may continue treatment if it still seems to help and they feel well.
  • There is no guarantee the study treatment will help you—but your participation could make a difference.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-small Cell Lung Cancer, NSCLC
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria:

  • Diagnosis of advanced or metastatic nonsquamous NSCLC that has spread to other parts of the body
  • Has a KRAS G12C mutation 

**Participants who are at least 18 years of age with treatment-naïve advanced or metastatic NSCLC whose tumors carry KRAS G12C mutation will be enrolled in the study. A test of the KRAS gene for G12C biomarker status will be used on a sample of the patient's tumor to determine if they qualify to participate.

Exclusion Criteria:

  • Has active, requiring Immunosuppressive medication or previous clear history of Crohn’s disease, ulcerative
    colitis, or chronic diarrhea
  • Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
  • Has received prior treatment for Stage III or IV lung cancer
  • Other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with safety, study compliance or data interpretation.

Updated on 03 Apr 2026. Study ID: ARN-MERCK-KANDLELIT-007, 29749

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team